2 Information about empagliflozin
Marketing authorisation indication
2.1 Empagliflozin (Jardiance, Boehringer Ingelheim) has a marketing authorisation 'in adults for the treatment of symptomatic chronic heart failure with reduced ejection fraction'.
Dosage in the marketing authorisation
2.2 The dosage schedule is available in the summary of product characteristics.